FDA
57 statements across 26 episodes · 18 bullish · 15 bearish · 23 people on the record · first statement Dec 15, 2017 by Jorge Conde · across every show →
Everything said about FDA, oldest first
Dec 15, 2017 positive
Dec 15, 2017 neutral
Apr 30, 2018
Pande: Reimbursement is a bigger hurdle for diagnostics startups than FDA approval
“Ironically, I think, you know, most people think about the FDA or CLIA being your big, ah, concern. I think reimbursement's probably the first place to start, because I wouldn't want to sort of be designing a test without having the confidence that I'll get re…”
Jan 2, 2019
Jan 2, 2019
Kindler: FDA only recently permitted direct electronic clinical data entry
“It was only relatively recently that the FDA Allowed clinical data to be entered directly into computers as opposed to put on paper because there was a reluctance to trust the quality and integrity of that data, which I think we would all agree is kind of sill…”
Jan 2, 2019
Jan 2, 2019
Jan 2, 2019
Jan 2, 2019 negative
Langer: Withdrawing Vioxx from the market in 2005 was wrong
“The second one that I think had a negative effect was the Vioxx situation in 2005, and, you know, there was just a small increase in deaths with this drug, but there were so many lawsuits over it, That people at the FDA would get called on the carpet for appro…”
Jan 2, 2019
Langer: Artificial hearts still use ladies' girdle material after 50 years
“If you wanted to make an artificial heart, what the clinicians did in 1967 is they said, well, what object in your house has a good flex life like a heart? And they came up with the idea of a lady's girdle. So they looked at what that was made out of, and It's…”
Jan 2, 2019 positive
Jan 2, 2019 positive
Jan 17, 2019 positive
Novartis launched first FDA-approved prescription app for opioid addiction
“I mean, one example we launched in the U S a digital medicine. I mean, with paratherapeutics, this is the first digital app with an FDA label that's being used for opioid addiction and other psychiatric illnesses. And it is literally an app That has run clinic…”
Jan 17, 2019 neutral
Jan 17, 2019
Feb 26, 2019 neutral
Feb 26, 2019 positive
Abernethy: Core FDA priorities will be evidence generation, personalized medicine, drug design
“When I'm at FDA, I will have a trans-FDA remit, so I will need to spend my time and energy working on the things that the FDA needs me to do, and I'm looking forward to learning more and more about that every day. But I know that I'll at least spend some of my…”
Apr 1, 2019 positive
Church: Regulators favor breakthrough therapeutic platforms over incremental updates
“To some extent, I think they like new technologies more than they like the old ones. The old ones tend to fail because they're so incremental that they're no longer compared to the placebo, they're compared to whatever they're in increment over, whatever thera…”
Oct 5, 2019 positive
Tran: FDA and CBER introduced accelerated approval guidance for gene therapies
“This past year we've seen FDA and CBER leaders drum up plans to make a big push on assessing new cell and gene therapies, as well as introducing new guidance on accelerated approvals for these new areas of product development.”
Jan 6, 2020 negative
Jan 6, 2020
Abernethy: FDA maintains an international bacterial genomic database to trace outbreaks
“And one of the things the FDA does in concert with CDC and now really through international database is have, is maintain a database of all the different genomes so that we can also track back and do this more quickly.”
Jan 6, 2020 positive
Abernethy: FDA pilots preconditions to allow medical software updates without full review
“Can we come up with, essentially, preconditions for software updates? So that if there are strong quality controls in the way software is developed, well understood product performance as an expect, in terms of the expectation updates, can you now have algorit…”
Jan 6, 2020 positive
Abernethy: FDA considers mobile app for consumers to trace produce supply chains
“One of the things we've been contemplating at FDA is, like, ultimately, could you imagine the application on your phone that allows you to scan peaches and understand did the peaches have a full supply chain that we can monitor?”
Jan 6, 2020 positive
Jan 6, 2020
Abernethy: Treatment evaluation will shift toward longitudinal performance tracking over time
“Historically, the way we've often thought about effectiveness is sort of as a fixed book of work, and I think that what you're going to see Over time is we're going to talk more and more about longitudinal performance, and this is a perfect example of that.”
Jan 6, 2020 negative
Jan 6, 2020
Abernethy: FDA can curb addiction by limiting post-surgical opioid prescriptions
“So practically speaking, we can help reduce the number of opioid tablets, for example, a patient has access to after back surgery or knee surgery in order to reduce the chance that this particular person has access and becomes addicted in the first place.”
Jan 6, 2020
Abernethy: FDA jurisdiction over DIY gene-editing requires commercial intent and labeling
“Practically speaking, if the kit was going to be approved for commercial purposes with claims and labeling, et cetera, that's when it starts to get into the FDA perspective. It gets really murky when we live in this landscape of the internet without claims.”
Jan 6, 2020 positive
Jan 6, 2020 neutral
Abernethy: FDA and USDA established a joint regulatory framework for cell-cultured food
“Last year we ultimately developed agreements with USDA so that the parts of the cell cultured food, food activity that's got to do with cell culture, for example, and that, that part of the equation ultimately became The FDA's responsibility, and then as we mo…”
Jan 6, 2020 neutral
Abernethy: Traditional boundaries between clinical trial phases are increasingly blurring
“And a drug or biologic will go through a series of clinical studies, typically phase one through three, although these days those lines are blurring for exactly what drugs, followed then by a new drug application or biologics application of BLA to the FDA.”
Jan 6, 2020
Jan 6, 2020
Abernethy: FDA does not directly regulate non-diagnostic healthcare workflow software
“So it may not necessarily be a software product that's acting As a diagnostic or treatment activity, but it's a software product that's intended to support life sciences more globally, whether that's to make clinical trials more efficient, to match patients to…”
Jan 6, 2020 neutral
Pande: FDA faces severe risk asymmetry from unapproved versus harmful drugs
“If there's a great drug that ah, that nobody ever gets, you know, nobody ever knows about it. Let's say there was a cure to cancer, but the FDA didn't approve it. There's no outcry because, ah, no one ever knew about it. But on the other hand, if the FDA let s…”
Jan 6, 2020
Jan 6, 2020 bullish
Abernethy: Emerging biology increases FDA responsibility to objectively assess safety
“And I would argue that in a time of rapidly emerging biology, when we've got more and more scientific innovations and potential products coming to bear, The need to make sure that we have an objective way of assessing safety and effectiveness and providing con…”
Jan 6, 2020 positive
Jan 6, 2020 negative
Nov 16, 2022 negative
Nov 16, 2022 negative
Nov 16, 2022 negative
Nov 16, 2022 negative
Balaji: FDA delay cost in lives equals delay duration times mortality reduction
“Basically, if you have a drug and it was held up by 10 years, and then once it was approved, it reduced morbidity and mortality by X percentage. That means FDA's delay of 10 years multiplied by that is how many lives it cost. Relative to just taking the risk a…”
Nov 16, 2022 bearish
Balaji Srinivasan: The FDA is holding back tens of trillions of dollars
“Once we can get a zone outside the FDA, once we can exit the FDA, people don't understand how bad the FDA is. Your entire life, it's like tens of trillions of dollars of values being held back by FDA. It's like incalculable how bad they are as an agency.”
Dec 12, 2023 positive
FDA creates new office and Warp Speed pilot for rare diseases
“The FDA is looking to the skies and taking a page out of the FAA's approach to aviation safety, rigorous yet adaptive. Recently launching its own new office for therapeutic products and piloting Operation Warp Speed for rare disease to create more transparent …”
Dec 12, 2023 positive
FDA approves first CRISPR gene editing therapy for sickle cell anemia
“The breaking news is that the first CRISPR therapy has been approved. This is a therapy for sickle cell anemia and beta thalassemia that was developed by a biopharmaceutical company called Vertex Pharmaceuticals, working with another company called CRISPR Ther…”
Dec 20, 2023 negative
Dec 20, 2023 negative
Dec 20, 2023 negative
Pande: FDA rejects new drugs that are cheaper but equal in efficacy
“If you had a drug that was as good as the best drug, but cheaper, That still can't get that won't go by the FDA because they actually has to be better than the last drug, even if it's not better scientifically, but it's better in other ways.”
Mar 13, 2024 neutral
May 9, 2024 negative
Horowitz: Restricting genetic data access will cost more lives than FDA saves
“I think that this is a interesting, like, weird misapplication of good intentions in a policy way that's probably going to Kill more people than ever get saved by every kind of health, FDA, et cetera, policy that we have”
Dec 18, 2024 positive
Sep 23, 2025
Bhattacharya: FDA will issue updated pregnancy guidelines for acetaminophen use
“There will be, yeah. So that's something that Dr. McCary, the FDA commissioner is working on. And there'll be also you know, changes in, in like how Medicare pays, Medicare, CMS, Medicare, and Medicaid pay for Leucovorin. So it's a cross-agency collaboration f…”
Oct 6, 2025 negative
Wang: Federal personnel costs are a minor part of US budget
“Personnel costs are not a giant aspect of America's budget, and arguably we need a lot more personnel in order to, you know, process drug discoveries and make the FDA much more efficient, Process high-skilled immigrant visas and have a much more functional gov…”
Nov 14, 2025 negative
Nuzhna: FDA regulation has continuously increased except during the AIDS crisis
“Since the birth of this industry, we only had increasing regulation over time. I think there was like only one time in history of biotech where we made it easier to develop and approve new drugs. And that was during the ACE crisis where AIDS patients were just…”
Nov 14, 2025 neutral
Mar 9, 2026 bullish